MetaCap

IRulya Therapeutics Balance Sheet

NASDAQ: IRLAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

39.88-0.06 (-0.15%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

IRulya Therapeutics financial position

At the end of fiscal 2025, IRulya Therapeutics reported total assets of $93.5 million, down 18.3% from a year earlier against total liabilities of $129.2 million. Shareholders' equity was negative at -$35.7 million, meaning liabilities exceed assets; this is often the result of large share buybacks or accumulated losses. The company held $5.8 million in cash and equivalents against $18.0 million of debt, a net debt position of $12.2 million.

The current ratio (current assets divided by current liabilities) was 0.53, meaning short-term obligations exceed short-term assets.

Summary generated from market data by MetaCap's automated system. Methodology

IRulya Therapeutics balance sheet (annual)

IRulya Therapeutics annual balance sheet
Fiscal year (USD)FY 20252025-12-31FY 20242024-12-31FY 20232023-12-31FY 20222022-12-31FY 20212021-12-31FY 20202020-12-31FY 20192019-12-31FY 20182018-12-31
Cash & Equivalents5.81M6.21M20.75M40.59M29.45M66.84M51.21M24.87M
Short-Term Investments11.94M34.57M54.31M45.60M37.08M66.98M48.65M46.84M
Receivables———0————
Total Current Assets22.90M44.04M77.44M93.75M111.67M137.86M106.06M72.58M
Property, Plant & Equipment595.00K315.00K234.00K393.00K263.00K427.00K709.00K283.00K
Goodwill—017.63M00———
Intangible Assets67.82M60.05M63.67M5.90M0———
Long-Term Investments——03.58M19.93M50.46M16.76M—
Total Assets93.52M114.48M167.90M103.91M133.23M189.47M124.37M72.88M
Accounts Payable2.22M2.90M2.03M570.00K4.91M3.56M3.08M495.00K
Short-Term Debt18.03M0——————
Total Current Liabilities43.23M7.28M9.57M3.07M14.22M17.00M8.89M1.46M
Long-Term Debt014.32M13.43M0————
Total Liabilities129.24M84.33M82.82M3.32M14.64M17.20M8.89M1.46M
Shareholders' Equity-35.71M30.15M85.08M100.59M118.59M172.26M115.48M-32.63M
Retained Earnings-460.45M-376.47M-319.64M-288.26M-236.60M-146.65M-69.81M-32.83M
Total Debt18.03M14.32M13.43M0————
Net Cash (Debt)-274.00K26.46M61.63M86.19M66.53M133.82M99.86M71.72M
Shares Outstanding278.63K44.00M42.97M36.14M30.07M29.54M26.87M3.41M

This table shows 8 annual periods of IRulya Therapeutics's balance sheet, from FY 2025 back to FY 2018, across 19 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow IRLA's reporting calendar. What is a balance sheet?

More financial data